CMRX250117P6000
- 3.05
- 0.000.00%
Chimerix Newsroom
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $7
Chimerix Announces NDA Submission For Dordaviprone - Quick Facts
Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug
Express News | Chimerix Inc - Enters Credit Facility of up to $30 Million With Svb
Chimerix Seeks FDA Approval for New Drug Targeting Deadly Brain Cancer
Express News | Chimerix Inc - Requests Priority Review for Nda
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27M-Mutant Diffuse Glioma
Top-rated Smaller Defensive Stocks After Societe Generale Permabear Takes Contrarian View
Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?
H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
Express News | HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans
CervoMed CRVO Phase 2b Fails; Chimerix SNDA Application
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings